Business
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”
Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client environments where proprietary data never leaves the client’s controlPlatform-as-a-service model designed to generate recurring revenue by licensing AI capabilities to biotech and pharmaceutical companies of all sizes — addressing a market where the top 20 pharma companies invested approximately $167 billion in R&D in 2024 bu
About this update from Kala Bio, Inc.
[{"type":"image","alt":"KALA BIO, Inc.","displaySize":"","headline":null,"caption":"KALA BIO, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":210,"url":"https://media.zenfs.com/en/globenewswire.com/5317c130ba58e5fbeca603a90c5b4c46"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/poFKt69Bd.mweg6BAiQGYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5317c130ba58e5fbeca603a90c5b4c46","width":300,"height":210}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client environments where proprietary data never leaves the client’s control","length":242,"tagName":"p"}]},{"val":[{"type":"text","content":"Platform-as-a-service model designed to generate recurring revenue by licensing AI capabilities to biotech and pharmaceutical companies of all sizes — addressing a market where the top 20 pharma companies invested approximately $167 billion in R&D in 2024 but have only recently begun to deploy meaningful AI budgets","length":320,"tagName":"p"}]},{"val":[{"type":"text","content":"KALA to serve as its own first deployment client, applying Researgency to its proprietary MSC-S biological datasets and KPI-012 clinical program before scaling to external biotech partners","length":188,"tagName":"p"}]},{"val":[{"type":"text","content":"Exclusive worldwide license secured for the Researgency platform in the biotechnology field for an initial 12-month term with successive renewal options; platform architecture designed from inception for multi-client deployment","length":227,"tagName":"p"}]},{"val":[{"type":"text","content":"On-premises, data-sovereign architecture will differentiate Researgency from centralized AI platforms — will enable biotechs to leverage institutional-grade AI without surrendering control of their most valuable intellectual property","length":233,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1210,"olType":false},{"type":"text","content":"ARLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”), a clinical-stage biopharmaceutical company, today announced a strategic initiative to build a biotechnology in...